
## Stefania Fasano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4165718/publications.pdf Version: 2024-02-01



STEEANIA FASANO

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Knockout of ERK1 MAP Kinase Enhances Synaptic Plasticity in the Striatum and Facilitates<br>Striatal-Mediated Learning and Memory. Neuron, 2002, 34, 807-820.   | 8.1 | 420       |
| 2  | Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.<br>Progress in Neurobiology, 2015, 132, 96-168.   | 5.7 | 379       |
| 3  | Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. Journal of Clinical Investigation, 2004, 113, 1118-1129.   | 8.2 | 256       |
| 4  | Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice.<br>Journal of Clinical Investigation, 2006, 116, 3070-3082.   | 8.2 | 197       |
| 5  | Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts<br>motor symptoms associated with <scp> </scp> -dopa–induced dyskinesia. Proceedings of the National<br>Academy of Sciences of the United States of America, 2010, 107, 21824-21829. | 7.1 | 141       |
| 6  | Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. Journal of Clinical Investigation, 2004, 113, 1118-1129.   | 8.2 | 117       |
| 7  | Knockout of ERK1 Enhances Cocaine-Evoked Immediate Early Gene Expression and Behavioral Plasticity.<br>Neuropsychopharmacology, 2006, 31, 2660-2668.  | 5.4 | 101       |
| 8  | Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) Controls Activation of Extracellular<br>Signal-Regulated Kinase (ERK) Signaling in the Striatum and Long-Term Behavioral Responses to<br>Cocaine. Biological Psychiatry, 2009, 66, 758-768.  | 1.3 | 96        |
| 9  | Impaired Bidirectional Synaptic Plasticity and Procedural Memory Formation in Striatum-Specific cAMP<br>Response Element-Binding Protein-Deficient Mice. Journal of Neuroscience, 2006, 26, 2808-2813.  | 3.6 | 93        |
| 10 | Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular<br>Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia. Biological<br>Psychiatry, 2015, 77, 106-115.   | 1.3 | 67        |
| 11 | Oligodendroglial Progenitor Cell Therapy Limits Central Neurological Deficits in Mice with<br>Metachromatic Leukodystrophy. Journal of Neuroscience, 2006, 26, 3109-3119.   | 3.6 | 60        |
| 12 | Ras?ERK Signaling in Behavior: Old Questions and New Perspectives. Frontiers in Behavioral Neuroscience, 2011, 5, 79.   | 2.0 | 51        |
| 13 | Safety of Arylsulfatase A Overexpression for Gene Therapy of Metachromatic Leukodystrophy. Human<br>Gene Therapy, 2007, 18, 821-836.  | 2.7 | 47        |
| 14 | Cellular Mechanisms of Striatum-Dependent Behavioral Plasticity and Drug Addiction. Current<br>Molecular Medicine, 2002, 2, 649-665.  | 1.3 | 45        |
| 15 | Multipotential Neural Precursors Transplanted into the Metachromatic Leukodystrophy Brain Fail to<br>Generate Oligodendrocytes but Contribute to Limit Brain Dysfunction. Developmental Neuroscience,<br>2008, 30, 340-357.   | 2.0 | 43        |
| 16 | Levodopa gains psychostimulantâ€like properties after nigral dopaminergic loss. Annals of Neurology,<br>2013, 74, 140-144.  | 5.3 | 43        |
| 17 | Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias. Journal of<br>Neuroscience, 2012, 32, 16106-16119.   | 3.6 | 39        |
| 18 | l-DOPA Impairs Proteasome Activity in Parkinsonism through D <sub>1</sub> Dopamine Receptor.<br>Journal of Neuroscience, 2012, 32, 681-691.   | 3.6 | 37        |

Stefania Fasano

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors. ELife, 2016, 5, .   | 6.0 | 35        |
| 20 | Severe Intellectual Disability and Enhanced Gamma-Aminobutyric Acidergic Synaptogenesis in a Novel Model of Rare RASopathies. Biological Psychiatry, 2017, 81, 179-192.  | 1.3 | 30        |
| 21 | Behavioral Methods for the Study of the Ras–ERK Pathway in Memory Formation and Consolidation:<br>Passive Avoidance and Novel Object Recognition Tests. Methods in Molecular Biology, 2014, 1120,<br>131-156.      | 0.9 | 29        |
| 22 | Inhibition of CREB activity in the dorsal portion of the striatum potentiates behavioral responses to drugs of abuse. Frontiers in Behavioral Neuroscience, 2009, 3, 29.   | 2.0 | 27        |
| 23 | MicelackingRas- GRF1 showcontextualfearcondition- ing butnotspatialmemoryimpair-<br>ments:convergentevidencefromtwo independentlygeneratedmousemutant lines. Frontiers in<br>Behavioral Neuroscience, 2011, 5, 78. | 2.0 | 27        |
| 24 | Cerebellar Neurons and Glial Cells Are Transducible by Lentiviral Vectors without Decrease of Cerebellar Functions. Developmental Neuroscience, 2006, 28, 216-221.   | 2.0 | 20        |
| 25 | Differential involvement of Rasâ€GRF1 and Rasâ€GRF2 in Lâ€DOPAâ€induced dyskinesia. Annals of Clinical and Translational Neurology, 2015, 2, 662-678.  | 3.7 | 19        |
| 26 | Antiâ€Parkinsonian and antiâ€dyskinetic profiles of two novel potent and selective nociceptin/orphanin<br>FQ receptor agonists. British Journal of Pharmacology, 2018, 175, 782-796.                               | 5.4 | 16        |
| 27 | Genetic enhancement of Ras-ERK pathway does not aggravate L-DOPA-induced dyskinesia in mice but prevents the decrease induced by lovastatin. Scientific Reports, 2018, 8, 15381.                                   | 3.3 | 11        |
| 28 | The Inhibition of RasGRF2, But Not RasGRF1, Alters Cocaine Reward in Mice. Journal of Neuroscience, 2019, 39, 6325-6338.   | 3.6 | 9         |
| 29 | RCS4 negatively modulates Nociceptin/Orphanin FQ opioid receptor signaling: implication for<br>Lâ€Dopaâ€induced dyskinesia British Journal of Pharmacology, 2021, , .  | 5.4 | 1         |
| 30 | 891. Correction of Established Neurologic Disease and Evidences of In Vivo Cross Correction in the<br>Mouse Model of Metachromatic Leukodystrophy. Molecular Therapy, 2006, 13, S343.                              | 8.2 | 0         |